Late cardiotoxicity after treatment for Hodgkin lymphoma.

By B. Aleman, A. W. van den Belt-Dusebout, M. D. De Bruin, M. B. van 't Veer, Margreet H. A. Baaijens, J. D. de Boer, A. Hart, W. J. Klokman, M. Kuenen, G. M. Ouwens and 2 more. Blood, 2007

748 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/18e78e0c85d769fc9f879db20a8dce182fe4d1f8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Gregory Y. H. Lip
2. Jeroen J. Bax
3. Helmut Baumgartner
4. Paulus Kirchhof
5. Jose Luis Zamorano
6. D. Lenihan
7. P. Lancellotti
8. Stephan Windecker

In Pathology and Forensic Medicine

1. Jeroen J. Bax

Citations in the corpus

• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “The risk of myocardial infarction in patients treated for Hodgkin lymphoma is two- to seven-fold higher than in the general population, with a cumulative incidence of 10% at 30 years.(7,81,99)”
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “The risk of myocardial infarction in patients treated for Hodgkin lymphoma is two- to seven-fold higher than in the general population, with a cumulative incidence of 10% at 30 years.(7,81,99)”